A Quebec study has shown many myocardial infarction patients are receiving reperfusion therapy outside recommended time windows, and this is putting them at increased risk of dying within 30 days.
A major meta-analysis of fibrate drugs has shown they modestly reduce the risk of major cardiovascular events, mainly through prevention of coronary artery disease and the need for revascularization.
